Cargando…

Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics

BACKGROUND: Speckle-type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor protein that functions as a potential tumor suppressor, and SPOP mutations have been identified in ~10% of human prostate cancers. However, it remains unclear if mutant SPOP proteins can be utilized as biomarkers for early...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hui, Barbieri, Christopher E., He, Jintang, Gao, Yuqian, Shi, Tujin, Wu, Chaochao, Schepmoes, Athena A., Fillmore, Thomas L., Chae, Sung-Suk, Huang, Dennis, Mosquera, Juan Miguel, Qian, Wei-Jun, Smith, Richard D., Srivastava, Sudhir, Kagan, Jacob, Camp, David G., Rodland, Karin D., Rubin, Mark A., Liu, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557563/
https://www.ncbi.nlm.nih.gov/pubmed/28810879
http://dx.doi.org/10.1186/s12967-017-1276-7
_version_ 1783257231866724352
author Wang, Hui
Barbieri, Christopher E.
He, Jintang
Gao, Yuqian
Shi, Tujin
Wu, Chaochao
Schepmoes, Athena A.
Fillmore, Thomas L.
Chae, Sung-Suk
Huang, Dennis
Mosquera, Juan Miguel
Qian, Wei-Jun
Smith, Richard D.
Srivastava, Sudhir
Kagan, Jacob
Camp, David G.
Rodland, Karin D.
Rubin, Mark A.
Liu, Tao
author_facet Wang, Hui
Barbieri, Christopher E.
He, Jintang
Gao, Yuqian
Shi, Tujin
Wu, Chaochao
Schepmoes, Athena A.
Fillmore, Thomas L.
Chae, Sung-Suk
Huang, Dennis
Mosquera, Juan Miguel
Qian, Wei-Jun
Smith, Richard D.
Srivastava, Sudhir
Kagan, Jacob
Camp, David G.
Rodland, Karin D.
Rubin, Mark A.
Liu, Tao
author_sort Wang, Hui
collection PubMed
description BACKGROUND: Speckle-type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor protein that functions as a potential tumor suppressor, and SPOP mutations have been identified in ~10% of human prostate cancers. However, it remains unclear if mutant SPOP proteins can be utilized as biomarkers for early detection, diagnosis, prognosis or targeted therapy of prostate cancer. Moreover, the SPOP mutation sites are distributed in a relatively short region with multiple lysine residues, posing significant challenges for bottom-up proteomics analysis of the SPOP mutations. METHODS: To address this issue, PRISM (high-pressure, high-resolution separations coupled with intelligent selection and multiplexing)-SRM (selected reaction monitoring) mass spectrometry assays have been developed for quantifying wild-type SPOP protein and 11 prostate cancer-derived SPOP mutations. RESULTS: Despite inherent limitations due to amino acid sequence constraints, all the PRISM-SRM assays developed using Arg-C digestion showed a linear dynamic range of at least two orders of magnitude, with limits of quantification ranged from 0.1 to 1 fmol/μg of total protein in the cell lysate. Applying these SRM assays to analyze HEK293T cells with and without expression of the three most frequent SPOP mutations in prostate cancer (Y87N, F102C or F133V) led to confident detection of all three SPOP mutations in corresponding positive cell lines but not in the negative cell lines. Expression of the F133V mutation and wild-type SPOP was at much lower levels compared to that of F102C and Y87N mutations; however, at present, it is unknown if this also affects the biological activity of the SPOP protein. CONCLUSIONS: In summary, PRISM-SRM enables multiplexed, isoform-specific detection of mutant SPOP proteins in cell lysates, providing significant potential in biomarker development for prostate cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-017-1276-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5557563
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55575632017-08-16 Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics Wang, Hui Barbieri, Christopher E. He, Jintang Gao, Yuqian Shi, Tujin Wu, Chaochao Schepmoes, Athena A. Fillmore, Thomas L. Chae, Sung-Suk Huang, Dennis Mosquera, Juan Miguel Qian, Wei-Jun Smith, Richard D. Srivastava, Sudhir Kagan, Jacob Camp, David G. Rodland, Karin D. Rubin, Mark A. Liu, Tao J Transl Med Research BACKGROUND: Speckle-type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor protein that functions as a potential tumor suppressor, and SPOP mutations have been identified in ~10% of human prostate cancers. However, it remains unclear if mutant SPOP proteins can be utilized as biomarkers for early detection, diagnosis, prognosis or targeted therapy of prostate cancer. Moreover, the SPOP mutation sites are distributed in a relatively short region with multiple lysine residues, posing significant challenges for bottom-up proteomics analysis of the SPOP mutations. METHODS: To address this issue, PRISM (high-pressure, high-resolution separations coupled with intelligent selection and multiplexing)-SRM (selected reaction monitoring) mass spectrometry assays have been developed for quantifying wild-type SPOP protein and 11 prostate cancer-derived SPOP mutations. RESULTS: Despite inherent limitations due to amino acid sequence constraints, all the PRISM-SRM assays developed using Arg-C digestion showed a linear dynamic range of at least two orders of magnitude, with limits of quantification ranged from 0.1 to 1 fmol/μg of total protein in the cell lysate. Applying these SRM assays to analyze HEK293T cells with and without expression of the three most frequent SPOP mutations in prostate cancer (Y87N, F102C or F133V) led to confident detection of all three SPOP mutations in corresponding positive cell lines but not in the negative cell lines. Expression of the F133V mutation and wild-type SPOP was at much lower levels compared to that of F102C and Y87N mutations; however, at present, it is unknown if this also affects the biological activity of the SPOP protein. CONCLUSIONS: In summary, PRISM-SRM enables multiplexed, isoform-specific detection of mutant SPOP proteins in cell lysates, providing significant potential in biomarker development for prostate cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-017-1276-7) contains supplementary material, which is available to authorized users. BioMed Central 2017-08-15 /pmc/articles/PMC5557563/ /pubmed/28810879 http://dx.doi.org/10.1186/s12967-017-1276-7 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wang, Hui
Barbieri, Christopher E.
He, Jintang
Gao, Yuqian
Shi, Tujin
Wu, Chaochao
Schepmoes, Athena A.
Fillmore, Thomas L.
Chae, Sung-Suk
Huang, Dennis
Mosquera, Juan Miguel
Qian, Wei-Jun
Smith, Richard D.
Srivastava, Sudhir
Kagan, Jacob
Camp, David G.
Rodland, Karin D.
Rubin, Mark A.
Liu, Tao
Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics
title Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics
title_full Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics
title_fullStr Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics
title_full_unstemmed Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics
title_short Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics
title_sort quantification of mutant spop proteins in prostate cancer using mass spectrometry-based targeted proteomics
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557563/
https://www.ncbi.nlm.nih.gov/pubmed/28810879
http://dx.doi.org/10.1186/s12967-017-1276-7
work_keys_str_mv AT wanghui quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT barbierichristophere quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT hejintang quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT gaoyuqian quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT shitujin quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT wuchaochao quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT schepmoesathenaa quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT fillmorethomasl quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT chaesungsuk quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT huangdennis quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT mosquerajuanmiguel quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT qianweijun quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT smithrichardd quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT srivastavasudhir quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT kaganjacob quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT campdavidg quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT rodlandkarind quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT rubinmarka quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics
AT liutao quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics